Abstract:The mechanistic target of rapamycin (mTOR) integrates growth factor signals with cellular nutrient and energy levels and coordinates cell growth, proliferation and survival. A regulatory network with multiple feedback loops has evolved to ensure the exquisite regulation of cell growth and division. Colorectal cancer is the most intensively studied cancer because of its high incidence and mortality rate. Multiple genetic alterations are involved in colorectal carcinogenesis, including oncogenic Ras activation, phosphatidylinositol 3-kinase pathway hyperactivation, p53 mutation, and dysregulation of wnt pathway. Many oncogenic pathways activate the mTOR pathway. mTOR has emerged as an effective target for colorectal cancer therapy. In vitro and preclinical studies targeting the mTOR pathway for colorectal cancer chemotherapy have provided promising perspectives. However, the overall objective response rates in major solid tumors achieved with single-agent rapalog therapy have been modest, especially in advanced metastatic colorectal cancer. Combination regimens of mTOR inhibitor with agents such as cytotoxic chemotherapy, inhibitors of vascular endothelial growth factor, epidermal growth factor receptor and Mitogen-activated protein kinase kinase (MEK) inhibitors are being intensively studied and appear to be promising. Further understanding of the molecular mechanism in mTOR signaling network is needed to develop optimized therapeutic regimens. In this paper, oncogenic gene alterations in colorectal cancer, as well as their interaction with the mTOR pathway, are systematically summarized. The most recent preclinical and clinical anticancer therapeutic endeavors are reviewed. New players in mTOR signaling pathway, such as non-steroidal anti-inflammatory drug and metformin with therapeutic potentials are also discussed here.

Research Progress of Mtor Signaling Pathway and Non-Small Cell Lung Cancer

Research Progress of mTOR Inhibitors in the Treatment of Renal Cell Carcinoma

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

Advance in Research on the Relationship Between Mtor Signaling Pathway and Tumors

PI3K/Akt/mTOR Signaling Pathway and Non-small Cell Lung Cancer

Mtor Signaling Pathway and Cancer

Correlation between mTOR signal pathway and radiosensitivity in non -small cell lung cancer

Progress in mTOR study

Mtor Signaling in Cancer and Mtor Inhibitors in Solid Tumor Targeting Therapy

Targeting Mtor for Cancer Therapy

Long Noncoding RNAs in the Mtor Signaling Network: Biomarkers and Therapeutic Targets

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.

Research progress of small molecule inhibitors targeting PI3K-Akt-mTOR pathway

Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)

Targeting Mtor Network in Colorectal Cancer Therapy

Significance of Mtor Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer

[Mtor Signal Pathway and Its Inhibitors in Antitumor Therapy: a Review].

Progress in Mtor Pathway and Mtor Targeted Anticancer Drugs

Research new progress on inhibitors antitumor of PI3K-mTOR signaling pathway

Targeting the Mtor Regulatory Network in Hepatocellular Carcinoma: Are We Making Headway?